Integrated Synthesis of Calcitriol and 26,27-Hexadeutero Calcitriol

Abstract

Calcitriol (1α,25-dihydroxyvitamin D₃, 1), a classical vitamin D drug, is indicated primarily in the treatment of patients with postmenopausal osteoporosis and renal osteodystrophy. In this study, a practical synthesis of calcitriol (1), from readily available commercial vitamin D₂ (5) via hub intermediate 18, has been accomplished in 9% overall yield. This semi-synthetic process embedded four prominent elements of vitamin D chemistry: (1) cheletropic sulfur dioxide (SO₂) adduction for the isomerization of the characteristic triene from (5Z,7E) to (5E,7E), or for the protection of the triene for selective ozonolysis of the side chain, and cheletropic extrusion of SO₂ from the adduct in ethanolic sodium bicarbonate to retrieve the triene; (2) direct, regio- and stereoselective 1α-hydroxylation of 3β-TBS-protected (5E)-calciferol intermediate 19 using selenium dioxide in the presence of N-methylmorpholine N-oxide as a re-oxidant in a hot mixture of methylene chloride and methanol; (3) nickel(0)-mediated conjugate addition of the 22-iodide 23 to electron-deficient ethyl acrylate followed by Grignard reaction with methylmagnesium bromide to construct the calcitriol side chain; and (4) triplet-sensitized photoisomerization of 26 to access the bioactive (5Z,7E)-triene in calcitriol (1). The high-performance liquid chromatography purities of batches of the synthesized calcitriol (1) were consistently more than 99.9%, with related substances listed in the USP 2023 and EP 11.0 well controlled. This robust process proved amenable to pilot scale-up and industrial production. 26,27-Hexadeutero calcitriol (4), a deuterium-labeled calcitriol derivative, is useful as the internal standard in the bioanalysis for the quantification of calcitriol in serum. 4 was efficiently synthesized in an integrated manner from hub intermediate 18 in 48% yield.

Keywords

calcitriol - deuterium-labeled calcitriol - vitamin D - practical synthesis - related substances

Introduction

DeLuca's group reported the isolation and identification of calcitriol (1α,25-dihydroxyvitamin D₃, 1) in 1971.[1] [2] In the same year, Kodicek's group suggested that this substance should properly be regarded as a hormone-controlling calcium metabolism.[3] Since then, great progress has been made in the knowledge of vitamin D₃ (cholecalciferol, 2) metabolism. It has been established that vitamin D₃ is metabolized in the liver to the major circulating metabolite, 25-hydroxyvitamin D₃ (3), which is transported to the kidney where it is transformed into calcitriol (1), the active hormonal form of vitamin D₃ ([Scheme 1]).[1]

Scheme 1 Metabolism of vitamin D₃ (2).

Calcitriol (1) was launched by F. Hoffmann-La Roche Ltd. (Roche) in 1978 under the brand name Rocaltrol. Approved by U.S. Food and Drug Administration, Rocaltrol is indicated in the management of secondary hyperparathyroidism and the resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis, and also in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.[4] Nowadays, calcitriol is used primarily in the treatment of patients with postmenopausal osteoporosis and renal osteodystrophy.

As the vitamin D hormone, calcitriol (1) has been an active subject in experimental and clinical research in a wide variety of therapeutic fields, such as the treatment of advanced osteoarthritis,[5] its effect on bone turnover markers in people with type 2 diabetes (T2DM) and stage 3 chronic kidney disease,[6] combinations of calcitriol with anticancer treatments for breast cancer,[7] its modulatory effects on post-ischemic immunity response,[8] the potential treatment of age-related hypertension,[9] the immunoregulatory effect of calcitriol on experimental autoimmune encephalomyelitis mice,[10] the proliferation inhibition and potential apoptosis induction in B16-F10 melanoma cells,[11] the protection against the serotonin-depleting effects of neurotoxic doses of methamphetamine,[12] and the application potential of calcitriol (1) as an adjunctive treatment for T2DM-associated periodontitis.[13]

26,27-Hexadeutero calcitriol (4), a deuterium-labeled calcitriol derivative, had been used as the internal standard in an immunoaffinity extraction-enabled sensitive LC/MS/MS (liquid chromatography with tandem mass spectrometry) method for quantification of calcitriol in serum.[14] Therefore, 4 is useful in analyzing pharmacokinetic parameters and determining bioequivalence of calcitriol dosage forms.

Calcitriol (1) is a complex chiral molecule that contains six chiral carbons and the characteristic 5(Z),7(E),l0(l9)-triene motif. The practical synthesis of calcitriol (1) is challenging and requires expertise in vitamin D chemistry. This article covers the successful development of an integrated approach for the synthesis of both calcitriol (1) and its deuterated derivative 4 during our research and development campaign of generic calcitriol API (active pharmaceutical ingredient) and soft capsule. Furthermore, this article provides a tutorial review of the evolving strategy of calcitriol synthesis and valuable insights into vitamin D chemistry.

Results and Discussion

According to retrosynthetic analysis, there are essentially two categories of reported synthetic routes to calcitriol (1), i.e., the semi-syntheses and the total syntheses.[15] [16] [17] The semi-syntheses are the dominant strategy for the large-scale preparation of calcitriol. They can be further stratified into two sub-categories that use steroid precursors and vitamin D₂ (ergocalciferol, 5) as the starting material, respectively.

Historically, Roche relied on the semi-synthesis from 3β-dehydroepiandrosterone (6) for the production of calcitriol (1) ([Scheme 2]).[18] [19] The introduction of the 1α-hydroxyl group was accomplished by fermentation of 6 to reach diol 7, which was converted into tosylate 8 in multiple steps. The coupling of 8 with the tert-butyldimethylsilyl (TBS)-protected acetylenic alcohol 9 followed by Pt/C catalytic hydrogenation and subsequent tetrabutylammonium fluoride (TBAF) cleavage of the silyl protective groups in refluxing tetrahydrofuran (THF) or 1,2-dimethoxyethane gave rise to the key intermediate, 1α,25-dihydroxycholesterol (Ro 21-3245) (12) . Calcitriol (1) could be obtained after photochemical cleavage of ring B and thermal isomerization. The weaknesses of this Roche process lie in limited supply of the starting material 6 produced by fermentation, the use of pyrophoric reagent n-butyllithium, and the difficulty encountered in deprotecting the 25-TBS-protected alcohol group in the trisilyl ether 11.

Scheme 2 Historical semi-synthetic industrial production of calcitriol (1) by Roche.

The semi-synthesis of calcitriol (1) from readily available vitamin D₂ (5) was first reported in 1986 by Barton, Hesse, and their colleagues,[20] and further optimized and developed by Leo and Roche scientists ([Scheme 3]).[21] [22] [23] This upgraded process has proven amenable to industrial production, thanks to four distinguished synthetic methods developed over time by genius scientists in the vitamin D field: (1) protection of the triene sensitive to ozonolysis by electrocyclic addition of sulfur dioxide (SO₂) and subsequent thermolysis of the SO₂ adduct in refluxing alcohol containing sodium hydrogen carbonate to restore the (5E,7E)-triene;[20] (2) direct, regio- and stereoselective lα-hydroxylation of the 3β-silyl-protected (5E)-calciferol derivative with selenium dioxide in the presence of N-methylmorpholine N-oxide (NMO) as a reoxidant in solvent mixtures containing methanol;[24] (3) installation of the calcitriol side chain by a nickel-mediated conjugate addition of 22-iodide 23 to electron-deficient ethyl acrylate followed by Grignard reaction with methylmagnesium bromide;[23] and (4) photoisomerization in the presence of a triplet sensitizer to build the required (5Z,7E)-triene in calcitriol (1).[22] [23]

Scheme 3 Synthesis of 1 and 4 from vitamin D₂ (5) via hub intermediate 18. Reagents and conditions: (a) (1) SO₂, CH₂Cl₂, –10°C, 1.25 hours; (2) TBSCl, imidazole, DMF, r.t., overnight; (b) (1) O₃, CH₂Cl₂–MeOH (3:1), –10°C, ca. 45 minutes; (2) NaBH₄, r.t., 2 hours; (c) I₂, imidazole, PPh₃, CH₂Cl₂, 5°C, 0.5 hours, then r.t., 2 hours; (d) Zn dust, ethyl acrylate, NiCl₂•6H₂O, pyridine, 65°C, 30 minutes, then 25°C, 2.5 hours; (e) 95% EtOH, NaHCO₃, reflux, 2 hours; (f) (1) MeOH–CH₂Cl₂ (1:1), NMO, SeO₂, reflux, 5 hours; (2) TBSCl, imidazole, CH₂Cl₂, reflux, r.t., 16 hours; (3) flash chromatography; (g) (1) 95% EtOH, NaHCO₃, reflux, 90 minutes; (2) MeOH–CH₂Cl₂ (1:1), NMO, SeO₂, reflux, 50 minutes; (h) SO₂, CH₂Cl₂, –10°C, 45 minutes; (i) (1) O₃, CH₂Cl₂-MeOH (3:1), –10°C, ca. 45 minutes; (2) NaBH₄, r.t., 2 hours; (j) I₂, imidazole, PPh₃, CH₂Cl₂, 10°C, 15 minutes, then r.t., 2.5 hours; (k) Zn dust, ethyl acrylate, NiCl₂•6H₂O, pyridine, 60°C, 30 minutes, then r.t., 2.5 hours; (l) 95% EtOH, NaHCO₃, reflux, 2.25 hours; (m) CH₃MgBr in Et₂O, THF, icebath, 15 minutes, then r.t., 3 hours; (n) n-Bu₄NF, THF, r.t., 5.5 hours; (o) hν, 9-AA, MeOH, 0°C, 2 hours; (p) CD₃MgI prepared in situ from magnesium powders and CD₃I in Et₂O, THF, 0°C, 30 minutes, then r.t., 1 hour; (q) n-Bu₄NF, THF, r.t., 8 hours; (r) hν, 9-AA, MeOH, –5–0°C. Note: yields in parentheses are those of our process.

Unlike the semi-syntheses, the total syntheses of calcitriol (1) have so far found minimal if any usefulness, in the commercial production of calcitriol (1), primarily due to cost, length, and scalability. Mourino and colleagues, for example, reported a convergent synthesis of calcitriol (1) from vitamin D₃ (2) and vinyl triflate 33, which was prepared from (S)-carvone in 45% yield ([Scheme 4]). However, this total synthesis was compromised by lengthy sequences, cryogenic reaction conditions, and expensive and/or hazardous reagents.[25] In addition, bioconversion of vitamin D₃ into calcitriol (1) has been actively investigated for potential bioindustrial manufacture of calcitriol (1).[26] [27]

Scheme 4 Total synthesis of calcitriol (1). Reagents and conditions: (a) (1) O₃, pyridine, –78°C, 2 hours; (2) NaBH₄, –78°C, 20 minutes × 3, then r.t., 1 hour; (b) (1) CF₃C(O₂)CH₃, CF₃COCH₃, CH₂Cl₂, –15°C, 16 hours; (2) i-Pr₂NEt, DMAP, MOMCl, CH₂Cl₂, r.t., 24 hours; (c) (1) Ph₃P = CHBr, NaHMDS, THF, –60°C, 3 hours, –40°C, 2 hours, then –5°C, 12 hours; (d) (1) t-BuLi, Et₂O, –78°C, 30 minutes; (2) ZnBr₂, THF, –10°C, 1 hour; (e) (Ph₃P)₄Pd, Et₃N, THF, –40°C, 15 minutes, then r.t., 2 hours; (f) (1) n-Bu₄NF, THF, r.t., 24 hours; (2) AG 50W-X4, MeOH.

In sharp contrast to the high volume of references dealing with the synthesis of calcitriol (1), there are only a handful of references pertinent to the preparation of 4. Mourino and colleagues documented a total synthesis of 4 from the lythgoe-inhoffen diol (35) and ring-A enyne 40 ([Scheme 5]) in 1993.[28] The drawbacks of this synthesis were lengthy route, ultrasonic conditions, cryogenic reactions, hazardous reagents, and need of careful monitoring to avoid over-reduction of the triple bond. In addition, De Luca et al disclosed semi-syntheses of 4 from homocholenic acid methyl ester derivatives.[29] The shortcomings of these syntheses were limited availability of starting materials, tedious operations, need for preparative thin layer chromatography (TLC) or normal-phase high-performance liquid chromatography (HPLC) for purifications, and low yields (<20%) for several steps.

Scheme 5 Total synthesis of 26,27-hexadeutero calcitriol (4). Reagents and conditions: (a) PPh₃, imidazole, I₂, –20°C, 15 minutes, then r.t., 1.5 hours; (b) PDC, CH₂Cl₂, r.t., 6 hours; (c) LDA, Tf₂NPh, THF, –78°C, 2 hours; (d) methyl acrylate, Zn, CuI, EtOH-H₂O (7:3), ))), r.t., 40 minutes; (e) (PPh₃)₂PdCl₂, Et₃N, DMF, 75°C, 1 hour; (f) H₂, quinoline, Lindlar catalyst, hexanes, r.t., 8 hours; (g) isooctane, reflux, 5 hours; (h) (1) CD₃MgI, THF, r.t., 10 hours; (2) n-Bu₄NF, r.t., 24 hours.

After a comprehensive review of the prior art of calcitriol synthesis, a semi-synthetic strategy utilizing bulk vitamin D₂ (5) as the starting material and (5E, 7E)-triene ester 18 as the hub intermediate, was adopted for its merits of well-established chemistry and robustness for scale-up.[21] [22] [23] This strategy also allowed for isotope labeling in the late stage of the synthesis by reacting deuterated Grignard reagent with hub intermediate 18, thus achieving an integrated synthesis of the title compounds, viz. 1 and 4 ([Scheme 3]).

As outlined in [Scheme 3], two alternative routes from sulfone 13 to ester 18, one colored in green (the green route) and the other colored in violet (the violet route), had been reported by industry chemists from Leo and Roche.[21] [22] [23] Reported overall yields of 18 based on vitamin D₂ (5) of the green and violet routes are 18 and 16%, respectively. In both routes, 1α-hydroxylation is the step with the lowest yield. Considering the heavy loss of yield in the late-stage 1α-hydroxylation of ester 17 in the green route, the violet route with an early-stage 1α-hydroxylation was selected for our in-house optimization and development. Thus, sulfone 13 derived from vitamin D₂ (5) was heated in refluxing 95% ethanol in the presence of sodium bicarbonate to extrude SO₂ to afford 3β-TBS-protected (5E,7E)-triene 19, a direct 1α-hydroxylation of which was accomplished with selenium dioxide/NMO combination in a hot mixture of methylene chloride and methanol (1:1) to give a ca. 6:1 mixture of 1α- and 1β-epimers, which was silylated with tert-butyldimethylsilyl chloride (TBSCl) and separated by silica gel chromatography to provide pure 1α-epimer 20 in 36% telescoping yield based on 5. After protection of the sensitive (5E,7E)-triene motif with liquid SO₂ adduction, 20 were ozonized at –10°C in a mixture of methylene chloride and methanol (3:1), and the formed ozonides were subjected to one-pot reduction with powdered sodium borohydride to furnish the sulfone alcohol 22 in 87% yield. Iodination of 22 with I₂/Ph₃P/imidazole in methylene chloride delivered the sulfone iodides 23 in 86% yield, which was subjected to stoichiometric nickel(0)-mediated conjugate addition to ethyl acrylate to furnish 24 in 84% yield. This conjugate addition is the key reaction for the elaboration of calcitriol side chain. Interestingly, a related catalytic nickel(0)-mediated conjugate addition had been reported by using 8.6% equiv. of nickel chloride hexahydrate and 39% equiv. of added water in a mixture of THF and pyridine (1:1) to affect the side chain carbon–carbon bond-forming reaction.[18] SO₂ was extruded from 24 in boiling 95% ethanol in the presence of sodium bicarbonate to deliver 18 in 86% yield. Taken together, our streamlined process via the violet route delivered hub intermediate 18 from vitamin D₂ (5) in 19% overall yield.

With hub intermediate 18 in hand, the synthesis of calcitriol (1) and its deuterated derivative 4 was accomplished in a straightforward manner ([Scheme 3]).[23] [28] A Grignard reaction of 18 with commercial methyl magnesium bromide solution in THF gave 25 in 86% yield, whose silyl-protective groups were cleaved by the treatment of a TBAF solution in THF to afford the crystalline triol 26 in 81% yield. 26 was subjected to photoisomerization by radiation with a tunable high-pressure mercury lamp in the presence of triplet-sensitizer 9-acetylanthracene (9-AA) to deliver calcitriol (1) in 60% yield after careful recrystallization from methyl formate. 26,27-Hexadeutero calcitriol (4) was prepared in an analogous way in 48% yield from 18. It is worth noting that in the Grignard reaction of 18, methylmagnesium-d ₃ iodide (CD₃MgI) was conveniently prepared in situ from magnesium powders and trideuteriomethyl iodide (methyl-d ₃ iodide), and used in excess to drive the reaction to complete.[30]

Related Substances of Calcitriol

As per U.S. Pharmacopeia 46–NF 41 (USP 2023), triazoline adduct of pre-calcitriol (44), trans-calcitriol (26), 1β-calcitriol (45), and methylene calcitriol (46) are listed as specified organic impurities. As per European Pharmacopoeia (Ph. Eur.) 11th Edition (EP 11.0), 44, 26, and 45, but not 46, are listed as specified impurities. Since 44 and 46 are synthetic route-dependent impurities, they are not expected to appear in calcitriol (1) prepared in our process. Thus, we focused on related substances 26 and 45 in our quality control of synthesized calcitriol (1). As shown in [Table 1], the related substances in three laboratory batches of calcitriol (1) conformed to the acceptance criteria defined in USP 2023 and EP 11.0.

Table 1 Related substances profile of laboratory batches of calcitriol (1)

Compd.	USP 2023 limits (%)	EP 11.0 limits (%)	201301[a]	201302[a]	201303[a]
Triazoline adduct of pre-calcitriol (44)	0.1	0.5	NA[b]	NA[b]	NA[b]
trans-Calcitriol (26)	0.25	0.5	0.05	0.02	0.04
1β-Calcitriol (45)	0.1	0.5	0.0	0.0	0.0
Methylene calcitriol (46)	0.25	NA[b]	NA[b]	NA[b]	NA[b]
Any unspecified impurity	0.1	0.1	<0.1	<0.1	<0.1
Total impurities	1.0	1.0	0.09	0.08	0.06

^a Calcitriol (1) batch No.

^b Not applicable.

Conclusion

A practical synthesis of calcitriol (1), from readily available commercial vitamin D₂ (5) via hub intermediate 18 in 9% overall yield, has been accomplished in our development campaign for calcitriol API. This semi-synthetic process featured four prominent components of vitamin D chemistry, which included (1) SO₂ adduction with 5,10(19)-diene 5 for the isomerization of (5Z,7E)- to (5E,7E)-triene, or with 5,10(19)-diene 20 for the protection of the sensitive triene before ozonolysis, (2) selective 1α-hydroxylation of 3β-TBS-protected (5E)-calciferol derivative 19 with the ratio of 1α- and 1β-epimers being ca. 6:1, (3) nickel(0)-mediated conjugate addition of the 22-iodide 23 to electron-deficient ethyl acrylate to construct the ester side chain in 24, and (4) triplet-sensitized photoisomerization to access the required (5Z,7E) configuration of the triene system in 1. The HPLC purities of three laboratory batches of calcitriol (1) were all more than 99.9%, with related substances listed in the USP 2023 and EP 11.0 well controlled. This rugged process proved amenable to pilot scale-up and commercial production. Furthermore, 26,27-hexadeutero calcitriol (4) was efficiently synthesized from hub intermediate 18 in 48% yield. In summary, we were able to achieve an integrated synthesis of both calcitriol (1) and its deuterium-labeled derivative 4, capitalizing on our relentless research and development in the vitamin D field.

Experimental Section

General

All solvents and reagents were obtained from commercial suppliers and used without further purification unless otherwise noted. Reaction progress was monitored by TLC using precoated glass-backed silica gel plates and visualized with UV detection at 254 nm or 5% phosphomolybdic acid in ethanol. Silica gel 300–400 mesh was employed for column chromatography purification. Solvent ratios are volume ratios. Evaporation of solvents was carried out on a rotary evaporator under reduced pressure. ¹H NMR and ¹³C NMR were recorded on either a Bruker Avance III 400 or a Bruker Avance III 600 spectrometer, and were obtained in either deuterated chloroform (CDCl₃) or deuterated acetone (acetone-d ₆). ¹H NMR and ¹³C NMR spectra were referenced to protons (CHCl₃, δ 7.26 ppm; acetone, δ 2.05 ppm) and carbons (CHCl₃, δ 77.0 ppm; acetone, δ 29.84 ppm) in the deuterated solvents, respectively. Chemical shifts are given in δ values and coupling constants are reported in hertz (Hz). Elemental analysis was performed on a ThermoScientific FLASH 2000 Organic Elemental Analyzer. Triplet-sensitized photoisomerization was carried out in a BiLon BL-GHX-V photochemical reactor.

(1α,3β,5E,7E)-1,3-Bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-25-ol (25)

To a stirred icebath-cooled solution of 18 (6.6 g, 10 mmol) in dry THF (33 mL) under argon was added dropwise 3 mol/L methylmagnesium bromide in diethyl ether (10 mL, 30 mmol) at 0 to 5°C.[23] Upon completion of the addition, the mixture was stirred at 0 to 5°C for 30 minutes and then at room temperature for 3 hours. The resulting reaction was cooled to –5°C, and carefully quenched with saturated aqueous ammonium chloride (66 mL). This was diluted with ethyl acetate (99 mL), washed with saturated brine (30 mL × 3), dried over anhydrous sodium sulfate, and evaporated in vacuo to furnish crude product, which was purified by silica gel chromatography (80% ethyl acetate in n-heptane as eluent) to give 25 (5.55 g, yield 86%) as a colorless foam. ¹H NMR (400 MHz, CDCl₃) δ 6.46 (d, J = 11.6 Hz, 1H, 6-CH), 5.83 (d, J = l1.6 Hz, 1H, 7-CH), 4.99 (s, 1H, 19-CH), 4.94 (s, 1H, 19-CH), 4.56–4.52 (m, 1H), 4.24–4.20 (m, 1H), 1.20 (s, 6H, 26-CH₃ and 27-CH₃), 0.95 (d, J =7.0 Hz, 3H, 21-CH₃), 0.90 (s, 9H, SiC(CH₃)₃), 0.85 (s, 9H, SiC(CH₃)₃), 0.54 (s, 3H, 18-CH₃), 0.09–0.03 (m, 12H, 2Si(CH₃)₂). ESI-MS (m/z): 645.52 [M + H]⁺, 667.50 [M + Na]⁺.

(1α,3β,5E,7E)-9,10-Secocholesta-5,7,10(19)-trien-l,3,25-triol (26)

A 1-L, three-necked, round-bottomed flask was charged with a solution of 25 (5.54 g, 8.6 mmol) in dry THF (15 mL) and 1 mol/L TBAF in THF (86 mL, 86 mmol). The solution was stirred under argon at 50°C for 1.5 hours, and then concentrated in vacuo. The residue was partitioned between ethyl acetate (150 mL) and half-saturated brine (150 mL). The organic phase was separated, and the aqueous phase was back-extracted with ethyl acetate (75 mL × 2). The combined extracts were washed with saturated brine (75 mL × 3), dried over anhydrous sodium sulfate, and evaporated in vacuo to give an off-white solid. This residue was slurried overnight under argon in a mixture of ethyl acetate and n-heptane (1:6, 100 mL), filtered, washed with n-heptane, and dried in vacuo to give 26 (2.86 g, 81%). ¹H NMR (600 MHz, CDCl₃) δ 6.57 (d, J = 11.5 Hz, 1H, 6-CH), 5.88 (d, J = 11.5 Hz, 1H, 7-CH), 5.12 (br d, J = 1.8 Hz, 1H, 19-CH), 4.96 (br s, 1H, 19-CH), 4.49 (dd, J = 6.0, 3.7 Hz, 1H), 4.25–4.20 (m, 1H), 2.89–2.83 (m, 2H), 2.26 (dd, J = 13.9, 8.5 Hz, 1H), 2.09 (dt, J = 13.8, 5.1 Hz, 1H), 2.03–2.01 (m, 2H), 2.01–1.99 (m, 1H), 1.89–1.88 (m, 1H), 1.86–1.84 (m, 1H), 1.70–1.69 (m, 1H), 1.68–1.67 (m, 1H), 1.57–1.48 (m, 2H), 1.45–1.43 (m, 1H), 1.43–1.41 (m, 1H), 1.39–1.38 (m, 2H), 1.37–1.36 (m, 1H), 1.31–1.30 (m, 1H), 1.30–1.27 (m, 2H), 1.21 (s, 6H, 26-CH₃ and 27-CH₃), 1.22–1.19 (m, 1H), 1.08–1.02 (m, 1H), 0.93 (d, J = 6.3 Hz, 3H, 21-CH₃), 0.55 (s, 3H, 18-CH₃). ¹³C NMR (151 MHz, CDCl₃) δ 151.61, 145.62, 132.72, 123.48, 115.93, 110.06, 71.36, 71.28, 65.99, 56.56, 56.50, 46.05, 44.44, 41.91, 40.47, 36.78, 36.40, 36.20, 29.45, 29.27, 29.16, 27.79, 23.65, 22.36, 20.84, 18.90, 12.23. ESI-MS (m/z): 439.32 [M + Na]⁺, 855.63 [2M + Na]⁺. Anal. Calcd. for C₂₇H₄₄O₃•0.25H₂O: C, 77.00; H, 10.65. Found: C, 76.99; H, 10.61.

lα,25-Dihydroxyvitamin D₃ (calcitriol, 1)

A solution of 26 (1.04 g, 2.5 mmol) and 9-acetylanthracene (9-AA) (0.055 g, 0.25 mmol) in methanol (400 mL), contained in a 1-L vessel in the BiLon photochemical reactor, was cooled to –5°C while purging with argon, and irradiated with a tunable high-pressure 1000 W mercury lamp until the reaction was complete by HPLC monitoring. Caution! Light from the mercury lamp is damaging to the eyes and skin. The solution was transferred to a 1-L, round-bottomed flask and concentrated in vacuo to give a foam, which was chromatographed on silica gel with gradient eluting of 60 to 90% ethyl acetate in petroleum ether (60–90°C). The appropriate fractions were collected, evaporated in vacuo, and crystallized from methyl formate under argon and protected from light to give 1 (0.63 g, 60% yield) as a white solid. ¹H NMR (600 MHz, acetone-d ₆) δ 6.28 (d, J = 11.2 Hz, 1H, 6-CH), 6.08 (d, J = 11.2 Hz, 1H, 7-CH), 5.31 (dd, J = 2.9, 1.5 Hz, 1H, 19-CH), 4.85 (dd, J = 3.0, 1.3 Hz, 1H, 19-CH), 4.42–4.36 (m, 1H), 4.19–4.13 (m, 1H), 4.07 (d, J = 4.7 Hz, 1H, 1-OH), 3.81 (d, J = 4.0 Hz, 1H, 3-OH), 3.28 (s, 1H, 25-OH), 2.85 (dd, J = 12.3, 4.4 Hz, 1H), 2.48 (dd, J = 13.5, 3.7 Hz, 1H), 2.28 (dd, J = 13.4, 6.0 Hz, 1H), 2.04–1.97 (m, 2H), 1.96–1.90 (m, 1H), 1.93–1.85 (m, 1H), 1.80 (ddd, J = 12.2, 8.4, 3.2 Hz, 1H), 1.70–1.61 (m, 2H), 1.58–1.21 (m, 12H), 1.14 (s, 6H, 26-CH₃ and 27-CH₃), 1.09–1.00 (m, 1H), 0.95 (d, J = 6.5 Hz, 3H, 21-CH₃), 0.56 (s, 3H, 18-CH₃). ¹³C NMR (151 MHz, acetone-d ₆) δ 150.45, 141.22, 136.46, 123.88, 118.75, 110.77, 70.32, 70.00, 66.75, 57.25, 56.90, 46.35, 46.14, 45.18, 44.13, 41.22, 37.29, 36.95, 29.77, 29.58 (mixed with solvent peak), 29.43, 28.28, 24.18, 22.91, 21.35, 19.18, 12.22. ESI-MS (m/z): 439.33 [M + Na]⁺, 855.67 [2M + Na]⁺. Anal. calcd for C₂₇H₄₄O₃: C, 77.83; H, 10.64. Found: C, 77.84; H, 10.68.

(1α,3β,5E,7E)-26,27-Hexadeuterio-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-25-ol (27)

To a stirred suspension of magnesium powders (1.33 g, 54.7 mmol) in dry diethyl ether (6 mL) under argon was added a solution of trideuteriomethyl iodide (methyl-d ₃ iodide) (6.33 g, 43.66 mmol) in dry diethyl ether (26 mL) dropwise at 0 to 5°C. Upon completion of the addition, the mixture was allowed to stir under reflux for 30 minutes. To the resulting methylmagnesium-d ₃ iodide (CD₃MgI) solution was added a solution of 18 (3.2 g, 4.85 mmol) in dry THF (16 mL) dropwise at 0 to 5°C.[23] The reaction mixture was allowed to stir at 0°C for 30 minutes, room temperature for 1 hour, and then quenched under cooling with careful addition of saturated aqueous ammonium chloride (15 mL). The quenched reaction was diluted with ethyl acetate (300 mL), washed with brine (100 mL × 3), dried over anhydrous sodium sulfate, and evaporated in vacuo to yield 27 in quantitative yield. The obtained 27 was free of 18, and used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃) δ 6.46 (d, J = 11.4 Hz, 1H), 5.83 (d, J = 11.4 Hz, 1H), 5.00–4.97 (m, 1H), 4.95–4.92 (m, 1H), 4.56–4.51 (m, 1H), 4.24–4.20 (m, 1H), 0.94 (d, J = 6.4 Hz, 3H, 21-CH₃), 0.90 (s, 9H, SiC(CH₃)₃), 0.87 (s, 9H, SiC(CH₃)₃), 0.55 (s, 3H, 18-CH₃), 0.07–0.06 (m, 12H, 2Si(CH₃)₂). ESI-MS (m/z): 651.37 [M + H]⁺, 1301.81 [2M + H]⁺.

(1α,3β,5E,7E)-26,27-Hexadeuterio-9,10-secocholesta-5,7,10(19)-trien-1,3,25-triol (28)

A 100-mL, three-necked, round-bottomed flask was charged with a solution of 27 obtained above (quantitative yield, 4.85 mmol) in anhydrous THF (36 mL) and 1 mol/L TBAF in THF (64 mL, 64 mmol). The resulting solution was stirred at room temperature under argon for 8 hours and concentrated in vacuo. The residue was partitioned between ethyl acetate (100 mL) and half-saturated brine (100 mL). The organic phase was separated, and the aqueous phase was back-extracted with ethyl acetate (50 mL × 2). The combined organic phase was washed with brine (50 mL × 3), dried over anhydrous sodium sulfate, and evaporated in vacuo to give a residue, which was chromatographed on silica gel with 50% ethyl acetate in petroleum ether (60–90°C) as eluent to afford 28 (1.64 g, 80% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 6.58 (d, J = 11.4 Hz, 1H), 5.89 (d, J = 11.5 Hz, 1H), 5.13 (d, J = 1.9 Hz, 1H), 4.97 (s, 1H), 4.52–4.47 (m, 1H), 4.27–4.21 (m, 1H), 2.90–2.81 (m, 2H), 0.95 (d, J = 6.4 Hz, 3H, 21-CH₃), 0.57 (s, 3H, 18-CH₃). ESI-MS (m/z): 445.49 [M + Na]⁺, 867.97 [2M + Na]⁺ .

26,27-Hexadeuterio-lα,25-dihydroxyvitamin D₃ (4)

A solution of 28 (0.35 g, 0.8 mmol) and 9-AA (0.018 g, 0.08 mmol) in methanol (250 mL), contained in a 500-mL vessel in the BiLon photochemical reactor, was cooled at –5 to 0°C while purging with argon, and irradiated with a tunable high-pressure 1000 W mercury lamp until the reaction was complete by HPLC monitoring. Caution! Light from the mercury lamp is damaging to the eyes and skin. The solution was transferred to a round-bottomed flask and concentrated in vacuo to give a foam, which was chromatographed on silica gel with gradient eluting of 60 to 90% ethyl acetate in petroleum ether (60–90°C). The appropriate fractions were collected, evaporated in vacuo, crystallized from methyl formate under argon and protected from light to give 4 (0.21 g, 60% yield) as a white solid. ¹H NMR (400 MHz, acetone-d ₆) δ 6.29 (d, J = 11.2 Hz, 1H), 6.09 (d, J = 11.1 Hz, 1H), 5.31 (dd, J = 2.9, 1.5 Hz, 1H), 4.86 (dd, J = 2.9, 1.3 Hz, 1H), 4.42–4.35 (m, 1H), 4.20–4.12 (m, 1H), 3.86 (d, J = 4.6 Hz, 1H), 3.05 (s, 1H), 2.86 (dd, J = 12.0, 4.3 Hz, 1H), 2.50 (dd, J = 12.9, 4.0 Hz, 1H), 2.28 (dd, J = 13.4, 6.1 Hz, 1H), 2.03–1.98 (m, 2H), 1.97–1.92 (m, 1H), 1.92–1.89 (m, 1H), 1.85–1.78 (m, 1H), 1.70–1.63 (m, 2H), 1.57–1.17 (m, 12H), 1.08–1.01 (m, 1H), 0.97 (d, J = 6.4 Hz, 3H, 21-CH₃), 0.58 (s, 3H, 18-CH₃). ESI-MS (m/z): 445.14 [M + Na]⁺, 867.33 [2M + Na]⁺.

Conflict of Interest

None declared.

• References

• 1 Suda T. Discovery of 1α,25-dihydroxyvitamin D₃ and its impact on basic and clinical medicine. Bitamin 1995; 69 (01) 1-14
• 2 Holick MF, Schnoes HK, DeLuca HF, Suda T, Cousins RJ. Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 1971; 10 (14) 2799-2804
• 3 Lawson DE, Fraser DR, Kodicek E, Morris HR, Williams DH. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971; 230 (5291) 228-230
• 4 Roche Hexagon. Labels for NDA 021068 (ROCALTROL (CALCITRIOL)),. Accessed January 15, 2024 at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process(ApplNo=021068
• 5 Xie C, Sun Q, Dong Y. et al. Calcitriol-loaded multifunctional nanospheres with superlubricity for advanced osteoarthritis treatment. ACS Nano 2023; 17 (13) 12842-12861
• 6 Stathi D, Fountoulakis N, Panagiotou A. et al. Impact of treatment with active vitamin D calcitriol on bone turnover markers in people with type 2 diabetes and stage 3 chronic kidney disease. Bone 2023; 166: 116581
• 7 Segovia-Mendoza M, García-Quiroz J, Díaz L, García-Becerra R. Combinations of calcitriol with anticancer treatments for breast cancer: an update. Int J Mol Sci 2021; 22 (23) 12741
• 8 Tajalli-Nezhad S, Mohammadi S, Atlasi MA. et al. Calcitriol modulate post-ischemic TLR signaling pathway in ischemic stroke patients. J Neuroimmunol 2023; 375: 578013
• 9 Hua R, Liu B, He W. et al. Calcitriol reverses age-related hypertension via downregulating renal AP1/AT₁R pathway through regulating mitochondrial function. Clin Exp Hypertens 2023; 45 (01) 2277653
• 10 Robat-Jazi B, Oraei M, Bitarafan S. et al. Immunoregulatory effect of calcitriol on experimental autoimmune encephalomyelitis (EAE) mice. Iran J Allergy Asthma Immunol 2023; 22 (05) 452-467
• 11 Sutedja EK, Amarassaphira D, Goenawan H. et al. Calcitriol inhibits proliferation and potentially induces apoptosis in B16–F10 cells. Med Sci Monit Basic Res 2022; 28: e935139
• 12 Cass WA, Peters LE. Calcitriol protects against reductions in striatal serotonin in rats treated with neurotoxic doses of methamphetamine. Neurochem Int 2023; 169: 105590
• 13 Wang Y, Huang M, Xu W, Li F, Ma C, Tang X. Calcitriol-enhanced autophagy in gingival epithelium attenuates periodontal inflammation in rats with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2023; 13: 1051374
• 14 Yuan C, Kosewick J, He X, Kozak M, Wang S. Sensitive measurement of serum 1α,25-dihydroxyvitamin D by liquid chromatography/tandem mass spectrometry after removing interference with immunoaffinity extraction. Rapid Commun Mass Spectrom 2011; 25 (09) 1241-1249
• 15 Zhu GD, Okamura WH. Synthesis of vitamin D (calciferol). Chem Rev 1995; 95 (06) 1877-1952
• 16 Bendik I, Holler U, Marty M, Schutz J, Labler L. Discovery of 1α,25-dihydroxyvitamin D3 and its impact on basic and clinical medicine. In: Elvers B. ed. Ullmann's Encyclopedia of Industrial Chemistry. Weinheim:: Wiley-VCH;; 2019: 1-15
• 17 Kametani T, Furuyama H. Synthesis of vitamin D3 and related compounds. Med Res Rev 1987; 7 (02) 147-171
• 18 Van Arnum SD, Moffet H, Carpenter BK. Process control limits from a laboratory study on the Ni(0)-mediated coupling of ethyl acrylate with a C-22 steroidal iodide: a case study on the role of experimental design in highly developed processes. Org Process Res Dev 2004; 8 (05) 769-776
• 19 Uskokovic MR, Narwid TA, Iacobelli JA, Baggiolini E. Process for the preparation of 1α,25-dihydroxycholecalciferol. U.S. Patent 3993675A. November, 1976
• 20 Andrews DR, Barton DHR, Hesse RH, Pechet MM. Synthesis of 25-hydroxy- and 1α,25-dihydroxy vitamin D₃ from vitamin D₂ (calciferol). J Org Chem 1986; 51 (25) 4819-4828
• 21 Calverley MJ. Synthesis of MC 903, a biologically active vitamin D metabolite analogue. Tetrahedron 1987; 43 (20) 4609-4619
• 22 Choudhry SC, Belica PS, Coffen DL. et al. Synthesis of a biologically active vitamin-D₂ metabolite. J Org Chem 1993; 58 (06) 1496-1500
• 23 Manchand PS, Yiannikouros GP, Belica PS, Madan P. Nickel-mediated conjugate addition. Elaboration of calcitriol from ergocalciferol. J Org Chem 1995; 60 (20) 6574-6581
• 24 Andrews DR, Barton DHR, Cheng KP. et al. A direct, regio- and stereoselective 1α-hydroxylation of (5E)-calciferol derivatives. J Org Chem 1986; 51 (09) 1635-1637
• 25 Gómez-Reino C, Vitale C, Maestro M, Mouriño A. Pd-catalyzed carbocyclization-Negishi cross-coupling cascade: a novel approach to 1α,25-dihydroxyvitamin D₃ and analogues. Org Lett 2005; 7 (26) 5885-5887
• 26 Kang DJ, Im JH, Kang JH, Kim KH. Whole cell bioconversion of vitamin D₃ to calcitriol using Pseudonocardia sp. KCTC 1029BP. Bioprocess Biosyst Eng 2015; 38 (07) 1281-1290
• 27 Abbas AM, Elkhatib WF, Aboulwafa MM, Hassouna NA, Aboshanab KM. Bioconversion of vitamin D₃ into calcitriol by Actinomyces hyovaginalis isolate CCASU- A11-2. AMB Express 2023; 13 (01) 73
• 28 Sestelo JP, Mascarenas JL, Castedo L, Mourino A. Ultrasonically induced conjugate addition of iodides to electron-deficient olefins and its application to the synthesis of side-chain analogs of the hormone lα,25-dihydroxyvitamin D₃ . J Org Chem 1993; 58 (01) 118-123
• 29 De Luca HF, Schnoes HK, Napoli JL, Fivizzani MA. Isotopically labeled vitamin D derivatives and processes for preparing same. U.S. Patent 4269777A. May, 1981
• 30 Zhang Q, Qi L, Zhang D. Preparing method of deuterated calcitriol, and intermediate thereof [in Chinese]. CN Patent 110885304B. April, 2022

Publication History

Received: 29 February 2024

Accepted: 26 April 2024

Article published online:
28 May 2024